# An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

> **NCT03077698** · PHASE2 · TERMINATED · sponsor: **Xenetic Biosciences, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Sodium Cridanimod
- **DRUG:** progestin therapy

## Key facts

- **NCT ID:** NCT03077698
- **Lead sponsor:** Xenetic Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-14
- **Primary completion:** 2020-07-17
- **Final completion:** 2020-07-17
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** The study was discontinued due to a change in development strategy and not due safety concern.
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03077698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03077698, "An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03077698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*